Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo: Everolimus + SSA (1 RCT; 39 participants)
Estimates of effects, ranking, and certainty of evidence for… may leads to lower everolimus + SSA (3 RCTs; 739 participants) compared with placebo (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus + SSA (3 RCTs; 739 participants) Estimates of effects, ranking, and certainty of evidence for… may leads to lower everolimus + SSA (3 RCTs; 739 participants) compared with placebo (low certainty). Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane Headline outcomes only | HR 0.38 [0.26, 0.57] | 3 studies · 739 participants | Low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus + SSA (1 RCT; 39 participants) It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes everolimus + SSA (1 RCT; 39 participants) compared with placebo (very low certainty). Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane Headline outcomes only | OR 15.1 [2.55, 88.9] | 1 study · 39 participants | Very low |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus + SSA (2 RCTs; 589 participants) Estimates of effects, ranking, and certainty of evidence for… probably leads to higher everolimus + SSA (2 RCTs; 589 participants) compared with placebo (moderate certainty). Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane Headline outcomes only | OR 2.89 [1.61, 5.19] | 2 studies · 589 participants | Moderate |
Estimates of effects, ranking, and certainty of evidence for different treatment options vs placebo Everolimus + SSA (1 RCT; 39 participants) It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes everolimus + SSA (1 RCT; 39 participants) compared with placebo (very low certainty). Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis (2021) · Cochrane Headline outcomes only | HR 0.12 [0.03, 0.54] | 1 study · 39 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta‐analysis 2021 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.